MXPA01013210A - Composiciones farmaceuticas y nutricionales que contienen acidos grasos esenciales y agentes que disminuyen en la homocisteina. - Google Patents
Composiciones farmaceuticas y nutricionales que contienen acidos grasos esenciales y agentes que disminuyen en la homocisteina.Info
- Publication number
- MXPA01013210A MXPA01013210A MXPA01013210A MXPA01013210A MXPA01013210A MX PA01013210 A MXPA01013210 A MX PA01013210A MX PA01013210 A MXPA01013210 A MX PA01013210A MX PA01013210 A MXPA01013210 A MX PA01013210A MX PA01013210 A MXPA01013210 A MX PA01013210A
- Authority
- MX
- Mexico
- Prior art keywords
- essential fatty
- homocysteine
- pharmaceutical
- fatty acids
- compositions containing
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract 3
- 235000004626 essential fatty acids Nutrition 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 235000016709 nutrition Nutrition 0.000 title 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 4
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 abstract 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 2
- 235000019152 folic acid Nutrition 0.000 abstract 2
- 239000011724 folic acid Substances 0.000 abstract 2
- 229960000304 folic acid Drugs 0.000 abstract 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000019158 vitamin B6 Nutrition 0.000 abstract 1
- 239000011726 vitamin B6 Substances 0.000 abstract 1
- 229940011671 vitamin b6 Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
La aplicacion combinada de por lo menos un acido graso esencial de la serie n-6 o de la serie n-3, opcionalmente junto con otro(s) acido(s) graso(s) esencial(es) de las series n-6 o n-3, junto con uno o mas agentes que disminuyen la homocisteina. El agente que disminuye la homocisteina esta seleccionado de vitamina B12, acido folico, un compuesto relacionado con el acido folico, que tenga actividad biologica similar, y vitamina B6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9916536.7A GB9916536D0 (en) | 1999-07-14 | 1999-07-14 | Nutritional or pharmaceutical compositions |
| PCT/GB2000/002681 WO2001003696A1 (en) | 1999-07-14 | 2000-07-11 | Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA01013210A true MXPA01013210A (es) | 2004-06-03 |
Family
ID=10857244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA01013210A MXPA01013210A (es) | 1999-07-14 | 2000-07-11 | Composiciones farmaceuticas y nutricionales que contienen acidos grasos esenciales y agentes que disminuyen en la homocisteina. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20050147665A1 (es) |
| EP (1) | EP1200085A1 (es) |
| JP (1) | JP2003504333A (es) |
| KR (1) | KR20020025088A (es) |
| CN (1) | CN1223346C (es) |
| AU (1) | AU6167800A (es) |
| BR (1) | BR0013157A (es) |
| CA (1) | CA2377502A1 (es) |
| CZ (1) | CZ200258A3 (es) |
| EE (1) | EE200200021A (es) |
| GB (1) | GB9916536D0 (es) |
| HK (1) | HK1042853A1 (es) |
| HU (1) | HUP0202342A3 (es) |
| IL (1) | IL147556A0 (es) |
| IS (1) | IS6205A (es) |
| MX (1) | MXPA01013210A (es) |
| NO (1) | NO20020090D0 (es) |
| NZ (1) | NZ516101A (es) |
| PL (1) | PL352185A1 (es) |
| RU (1) | RU2001134300A (es) |
| SK (1) | SK332002A3 (es) |
| TR (1) | TR200200045T2 (es) |
| WO (1) | WO2001003696A1 (es) |
| ZA (1) | ZA200200259B (es) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7226916B1 (en) | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
| ITMI20010129A1 (it) | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
| KR20020069539A (ko) * | 2001-02-26 | 2002-09-05 | 주식회사 두산 | 뇌세포 보호용 조성물 |
| KR100427637B1 (ko) * | 2001-06-05 | 2004-04-27 | 이인규 | 세포내 에너지 소비 증가제 |
| JPWO2002102364A1 (ja) * | 2001-06-18 | 2004-09-30 | 山田 幸子 | ＰＰＡＲγ作動性医薬組成物 |
| JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| NL1019368C2 (nl) * | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
| US8729124B2 (en) | 2002-03-05 | 2014-05-20 | Pronova Biopharma Norge As | Use of EPA and DHA in secondary prevention |
| EP1515714B1 (en) * | 2002-06-17 | 2009-08-12 | Medestea Research & Production S.p.A. | Long chain unsaturated oxygenated compounds and their use in the therapeutical, cosmetic and nutraceutical field |
| DK1560589T3 (da) | 2002-06-20 | 2007-02-12 | Astion Dermatology As | Hidtil ukendte komplekser af fedtsyreestere af polyhydroxyalkaner og niacinamid |
| CA2492781A1 (en) * | 2002-07-11 | 2004-01-22 | Sankyo Company Limited | Medicinal composition for mitigating blood lipid or lowering blood homocystein |
| JP4611622B2 (ja) * | 2002-07-11 | 2011-01-12 | 第一三共株式会社 | 血中脂質改善又は血中ホモシステイン低下のための医薬組成物 |
| US20040132819A1 (en) * | 2002-08-06 | 2004-07-08 | Nancy Auestad | Appetite control method |
| CA2499501A1 (en) * | 2002-09-27 | 2004-04-08 | Martek Biosciences Corporation | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
| KR20040063616A (ko) * | 2003-01-08 | 2004-07-14 | 김원호 | 다이어트 식품용 조제 |
| JP2005082523A (ja) * | 2003-09-08 | 2005-03-31 | Toru Hasegawa | 神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬 |
| JP4522075B2 (ja) | 2003-10-29 | 2010-08-11 | サントリーホールディングス株式会社 | 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| ITMI20040069A1 (it) | 2004-01-21 | 2004-04-21 | Tiberio Bruzzese | Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale |
| JP2007532605A (ja) * | 2004-04-16 | 2007-11-15 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 冠性心疾患または冠状動脈疾患を持つ患者の鬱病の予防および／または治療における必須脂肪酸 |
| CA2577345C (en) * | 2004-08-18 | 2013-02-19 | Hiroki Ueshima | Jelly composition |
| JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
| WO2006054757A1 (ja) * | 2004-11-16 | 2006-05-26 | Astellas Pharma Inc. | カスパーゼ阻害剤 |
| US20060217385A1 (en) * | 2005-03-10 | 2006-09-28 | Edwards John B | Nutritional preparations |
| EP1879586A1 (en) * | 2005-03-10 | 2008-01-23 | Sciele Pharma, Inc. | Nutritional preparations comprising folates and essential fatty acids |
| JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および／又はうつ症状の改善作用を有する組成物 |
| US20070004639A1 (en) * | 2005-07-01 | 2007-01-04 | Bodybio, Inc. | Methods and compositions for treating Parkinson's disease |
| AU2006301389B9 (en) * | 2005-08-26 | 2011-05-12 | Société des Produits Nestlé S.A. | Nutrition for obese patients |
| BRPI0618455A2 (pt) * | 2005-11-11 | 2011-08-30 | Mochida Pharm Co Ltd | composição de geléia |
| US8367121B2 (en) * | 2005-11-23 | 2013-02-05 | Florida A & M University | Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease |
| JP5176127B2 (ja) * | 2006-01-11 | 2013-04-03 | 大正製薬株式会社 | 視覚機能障害の予防または改善剤 |
| US20090311329A1 (en) * | 2006-04-20 | 2009-12-17 | Technion Research And Development Foundation Ltd | Casein micelles for nanoencapsulation of hydrophobic compounds |
| JP5300186B2 (ja) * | 2006-08-23 | 2013-09-25 | 株式会社明治 | 血中ホモシステイン濃度の上昇を抑制する妊婦用の乳由来組成物 |
| KR100832675B1 (ko) * | 2006-09-22 | 2008-05-26 | 한상왕 | 영양 보조제 |
| WO2008081989A1 (ja) | 2006-12-28 | 2008-07-10 | Suntory Holdings Limited | 神経再生剤 |
| US8343541B2 (en) * | 2007-03-15 | 2013-01-01 | Soft Gel Technologies, Inc. | Ubiquinol and alpha lipoic acid compositions |
| WO2008153220A1 (ja) * | 2007-06-13 | 2008-12-18 | Suntory Holdings Limited | 血管疾患の予防又は治療剤 |
| WO2009002148A1 (en) * | 2007-06-27 | 2008-12-31 | N.V. Nutricia | Food composition for prodromal dementia patients |
| CA2692309C (en) * | 2007-06-26 | 2016-08-16 | N.V. Nutricia | Improving memory in subjects with mini-mental state examination of 24-26 |
| JP5798717B2 (ja) * | 2007-10-25 | 2015-10-21 | ニュートリー株式会社 | 血中の糖、マロンジアルデヒド修飾ｌｄｌ、ホモシステイン及び／又はｃ反応性タンパク質を低減するための組成物 |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| NZ600721A (en) * | 2008-01-10 | 2013-03-28 | Takeda Pharmaceutical | Capsule formulation |
| US20110236476A1 (en) | 2008-09-02 | 2011-09-29 | Amarin Corporation Plc. | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| US8865733B2 (en) * | 2008-11-06 | 2014-10-21 | Altman Enterprises, LLC | Medication and treatment for disease |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| SG10201605794PA (en) | 2009-04-29 | 2016-09-29 | Amarin Pharmaceuticals Ie Ltd | Stable Pharmaceutical Composition And Methods Of Using Same |
| WO2010127099A2 (en) * | 2009-04-29 | 2010-11-04 | Amarin Corporation Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| CN108096209A (zh) | 2009-06-15 | 2018-06-01 | 阿马里纳制药公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
| WO2011038122A1 (en) | 2009-09-23 | 2011-03-31 | Amarin Corporation Plc | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| WO2011100550A2 (en) | 2010-02-12 | 2011-08-18 | Alexander Vuckovic, M.D., Llc | Compositions and methods for treating depression |
| EP2646013A4 (en) | 2010-11-29 | 2014-03-26 | Amarin Pharma Inc | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US9216209B1 (en) | 2011-06-06 | 2015-12-22 | Kilmer S. McCully | Compositions and method for utilization of thioretinamide in therapy of degenerative diseases of aging |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| JP6307442B2 (ja) | 2012-01-06 | 2018-04-04 | アマリン ファーマシューティカルス アイルランド リミテッド | 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法 |
| EP2827839B1 (en) | 2012-03-20 | 2019-02-27 | Particle Dynamics International, LLC | Gelling agent-based dosage form |
| SMT202500326T1 (it) | 2012-06-29 | 2025-11-10 | Amarin Pharmaceuticals Ie Ltd | Estere etilico dell’acido eicosapentaenoico per l’uso nella riduzione del rischio di ictus non fatale in un soggetto in terapia con statine |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
| US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| CN103432156A (zh) * | 2013-08-30 | 2013-12-11 | 深圳奥萨医药有限公司 | ω-3脂肪酸和B族维生素的药物组合物及其用途 |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| GB201405033D0 (en) * | 2014-03-20 | 2014-05-07 | Isis Innovation | Combination therapy |
| WO2015142500A2 (en) | 2014-03-21 | 2015-09-24 | Bodybio Inc. | Compositions and methods for treating addiction |
| US10052339B2 (en) | 2014-03-21 | 2018-08-21 | Bodybio Inc. | Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids |
| EP3151825B1 (en) | 2014-06-04 | 2020-03-25 | DS Biopharma Limited | Pharmaceutical compositions comprising dgla and use of same |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| WO2016205754A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Compositions and methods for modified nutrient delivery |
| WO2016205701A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Enteral fast access tract platform system |
| CA3005983A1 (en) * | 2015-11-23 | 2017-06-01 | Retrotope, Inc. | Site-specific isotopic labeling of 1,4-diene systems |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| WO2018144088A1 (en) | 2016-11-03 | 2018-08-09 | Alexander Vuckovic, M.D., Llc | Compositions and methods for treating depression |
| WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| EP3700518A4 (en) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ireland Limited | METHODS OF REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT |
| CN114980973A (zh) | 2019-11-12 | 2022-08-30 | 阿马里纳药物爱尔兰有限公司 | 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法 |
| IL321252A (en) | 2020-02-21 | 2025-08-01 | Retrotope Inc | Processes for isotopic alteration of polyunsaturated fatty acids and their derivatives |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| EP4326244A4 (en) | 2021-04-21 | 2025-03-19 | Amarin Pharmaceuticals Ireland Limited | METHODS TO REDUCE THE RISK OF HEART FAILURE |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4237118A (en) * | 1972-03-06 | 1980-12-02 | Howard Alan N | Dietary supplement and dietary methods employing said supplement for the treatment of obesity |
| GB8719988D0 (en) * | 1987-08-25 | 1987-09-30 | Efamol Ltd | Chemical compounds |
| US5895652A (en) * | 1996-07-29 | 1999-04-20 | Longevity Institute International | Method of metabolic adjuvanation and cellular repair |
| GB9715203D0 (en) * | 1997-07-19 | 1997-09-24 | Piper Edwina M | Composition |
-
1999
- 1999-07-14 GB GBGB9916536.7A patent/GB9916536D0/en not_active Ceased
-
2000
- 2000-07-11 AU AU61678/00A patent/AU6167800A/en not_active Abandoned
- 2000-07-11 CN CNB008103399A patent/CN1223346C/zh not_active Expired - Fee Related
- 2000-07-11 EE EEP200200021A patent/EE200200021A/xx unknown
- 2000-07-11 MX MXPA01013210A patent/MXPA01013210A/es unknown
- 2000-07-11 CZ CZ200258A patent/CZ200258A3/cs unknown
- 2000-07-11 PL PL00352185A patent/PL352185A1/xx not_active Application Discontinuation
- 2000-07-11 CA CA002377502A patent/CA2377502A1/en not_active Abandoned
- 2000-07-11 NZ NZ516101A patent/NZ516101A/xx unknown
- 2000-07-11 JP JP2001508976A patent/JP2003504333A/ja active Pending
- 2000-07-11 SK SK33-2002A patent/SK332002A3/sk unknown
- 2000-07-11 WO PCT/GB2000/002681 patent/WO2001003696A1/en not_active Ceased
- 2000-07-11 HU HU0202342A patent/HUP0202342A3/hu unknown
- 2000-07-11 BR BR0013157-1A patent/BR0013157A/pt not_active IP Right Cessation
- 2000-07-11 KR KR1020017016625A patent/KR20020025088A/ko not_active Ceased
- 2000-07-11 RU RU2001134300/14A patent/RU2001134300A/ru not_active Application Discontinuation
- 2000-07-11 IL IL14755600A patent/IL147556A0/xx unknown
- 2000-07-11 TR TR2002/00045T patent/TR200200045T2/xx unknown
- 2000-07-11 EP EP00948105A patent/EP1200085A1/en not_active Withdrawn
- 2000-07-11 HK HK02104664.5A patent/HK1042853A1/zh unknown
-
2001
- 2001-12-18 IS IS6205A patent/IS6205A/is unknown
-
2002
- 2002-01-08 NO NO20020090A patent/NO20020090D0/no unknown
- 2002-01-11 ZA ZA200200259A patent/ZA200200259B/xx unknown
-
2004
- 2004-11-24 US US10/995,533 patent/US20050147665A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1361690A (zh) | 2002-07-31 |
| HUP0202342A3 (en) | 2003-02-28 |
| EP1200085A1 (en) | 2002-05-02 |
| IS6205A (is) | 2001-12-18 |
| TR200200045T2 (tr) | 2002-05-21 |
| SK332002A3 (en) | 2002-12-03 |
| US20050147665A1 (en) | 2005-07-07 |
| RU2001134300A (ru) | 2003-08-27 |
| WO2001003696A1 (en) | 2001-01-18 |
| KR20020025088A (ko) | 2002-04-03 |
| PL352185A1 (en) | 2003-08-11 |
| IL147556A0 (en) | 2002-08-14 |
| NO20020090L (no) | 2002-01-08 |
| NZ516101A (en) | 2003-06-30 |
| CN1223346C (zh) | 2005-10-19 |
| AU6167800A (en) | 2001-01-30 |
| HUP0202342A2 (hu) | 2002-11-28 |
| JP2003504333A (ja) | 2003-02-04 |
| HK1042853A1 (zh) | 2002-08-30 |
| GB9916536D0 (en) | 1999-09-15 |
| NO20020090D0 (no) | 2002-01-08 |
| BR0013157A (pt) | 2002-04-02 |
| EE200200021A (et) | 2003-04-15 |
| CA2377502A1 (en) | 2001-01-18 |
| ZA200200259B (en) | 2002-12-24 |
| CZ200258A3 (cs) | 2002-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA01013210A (es) | Composiciones farmaceuticas y nutricionales que contienen acidos grasos esenciales y agentes que disminuyen en la homocisteina. | |
| ATE87825T1 (de) | Zusammensetzungen essentieller fettsaeuren. | |
| TNSN05189A1 (en) | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis | |
| DE69720787D1 (de) | Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure | |
| HUP0303391A3 (en) | Aliphatic nitrogenous five-membered ring compounds, process for their preparation, pharmaceutical compositions containing them and their use | |
| BR0112094A (pt) | Produtos de confeitaria contendo ingredientes ativos | |
| IL158131A0 (en) | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism | |
| DE69836335D1 (de) | Natürliche inhaltsstoffe enthaltende nahrungsergänzungsstoffe | |
| CA2078019A1 (en) | Substance or composition and uses thereof | |
| PT824152E (pt) | Producao microbiana de vitamina b12 e producao e utilizacao de composicoes contendo elevadas concentracoes de actividade de vitamina b12 | |
| CA2332174A1 (en) | Nutritional supplement based on blackcurrant seed oil | |
| PT1411960E (pt) | Produto alimentar enriquecido a base de farelo de arroz para promocao da saude cardiovascular | |
| DE60008127D1 (de) | Diät mit hohem lipidgehalt | |
| ATE238805T1 (de) | Multifunktionelle formulierung für fettabsorbierung und zur senkung des cholesterolgehaltes im blut, welche chitosan und nicotinsäure enthält | |
| IE862351L (en) | Pharmaceutical compositions | |
| DE69809944D1 (de) | Fettsäuren als eine nährungsergänzung | |
| NO891220L (no) | Middel som inneholder salicylsyre for behandling av lepidose. | |
| DE69819519D1 (de) | Bergamottin enthaltende zusammensetzungen zur erhöhung der oralen bioverfügbarkeit von pharmazeutika | |
| AU2003224107A1 (en) | Soluble composition containing sporopollenin and the use thereof | |
| FR2426044A2 (fr) | Derives de la vitamine d3 ayant une activite anti-vitamine d | |
| ATE285757T1 (de) | Inaktivierte mikroorganismen, die pharmakologisch aktive substanzen enthalten | |
| ATE106883T1 (de) | Azelastin-embonat, verfahren zu seiner herstellung und pharmazeutische zubereitungen, die als wirkstoff azelastin-embonat enthalten. | |
| ATE301469T1 (de) | Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase | |
| DK1497250T3 (da) | Hyperforinderivater, anvendelse heraf og sammensætninger indeholdende disse | |
| UA64074C2 (uk) | Кардіопротекторний антиоксидантний засіб "елгацин" |